Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Computed Tomography
  • Drug: Copper Cu 64-DOTA B-Fab
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Diagnostic Test: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

Ovarian Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo
   surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian
   cancer but is not a surgical candidate

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Breast Cancer Participants

   1. Patient is ≥ 18 years old at the time of the drug administration

   2. Participant has biopsy proven breast cancer and may or may not undergo surgical
   excision of the cancerous lesion(s)

   3. Ability to understand and the willingness to sign a written informed consent document.

   4. Patient is able to remain still for duration of each imaging procedure

Exclusion Criteria:

Ovarian Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Breast Cancer Participants

   1. Patient is pregnant or breast-feeding

   2. Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or
   other study procedures.

   3. Patients with serious uncontrolled concurrent medical illness that would limit
   compliance with study requirements

   4. Patients participating in other research imaging protocols will be excluded from this
   study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting